Fetal diagnosis of hypoplastic left heart, associations and outcomes in the current era

R Axt-Fliedner1, C Enzensberger1, N Fass1

  • 1Division of Prenatal Medicine, Department of OB/GYN, Justus-Liebig-University, Giessen.

Ultraschall in Der Medizin (Stuttgart, Germany : 1980)
|December 20, 2012
PubMed

Insights

Prenatal diagnosis of Hypoplastic Left Heart (HLH) allows for informed decisions. Overall survival after fetal diagnosis is 40.9%, with higher rates for surgical candidates.

Area of Science:

  • Fetal Cardiology
  • Pediatric Cardiac Surgery
  • Prenatal Diagnosis

Background:

  • Hypoplastic Left Heart (HLH) is a common congenital heart defect diagnosed prenatally.
  • Antenatal diagnosis of HLH is crucial for parental counseling and treatment planning.

Purpose of the Study:

  • To report outcome data for Hypoplastic Left Heart (HLH) following fetal diagnosis.
  • To assess survival rates and factors influencing outcomes in HLH cases diagnosed antenatally.

Main Methods:

  • Retrospective analysis of 105 HLH cases diagnosed prenatally between 1994 and 2011.
  • Inclusion of data from two tertiary referral centers specializing in prenatal diagnosis and pediatric cardiology.

Main Results:

  • Overall survival after prenatal diagnosis was 40.9% (43/105).
  • Survival rates were 81.1% for infants undergoing surgery and 64.1% from an intention-to-treat perspective.
  • Associated extracardiac or karyotype anomalies were present in 18.9% of cases, often leading to compassionate care decisions or termination of pregnancy.

Conclusions:

  • Antenatal evaluation for HLH should include karyotyping and detailed anomaly assessment to predict surgical risks.
  • Exclusion of additional anomalies can refine prenatal counseling.
  • These findings provide current data to support parental counseling for HLH.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Fetal Circulation01:14

Fetal Circulation

Fetal circulation is a unique system that facilitates the exchange of gases, nutrients, and waste products between the developing fetus and the mother. This intricate process takes place through a special organ called the placenta.
Two umbilical arteries transport blood from the fetus to the placenta. At the placenta, the blood absorbs oxygen and nutrients while simultaneously eliminating waste products. This oxygen-enriched and nutrient-rich blood then returns to the fetus through one...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Development of the Heart01:27

Development of the Heart

The development of the human heart, a crucial organ, commences from the mesoderm on the 18th or 19th day after fertilization. This process initiates in the cardiogenic area, a group of mesodermal cells at the embryo's head end, which evolves into elongated strands known as cardiogenic cords. These cords undergo a transformation to form hollow-centered endocardial tubes.
As the embryo undergoes lateral folding, these paired tubes approach each other, merging into a single primitive heart tube by...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...